Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ceftazidime-avibactam plus metronidazole vs meropenem for complicated intra-abdominal infection
2011-003893-97Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2011
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftazidime + avibactam in Intra-abdominal infection (IAI) (2 arms), sponsored by AstraZeneca. Primary endpoint: Clinical cure at test-of-cure (TOC) in microbiological modified intent-to-treat (mMITT) population. Started Nov 2011; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2011-003893-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003893-97.